Controversies in Multiple Myeloma: Evidence Based Update

The U.S. Food and Drug Administration approved ten new drugs for the treatment of multiple myeloma over the last two decades. The influx of new anti-myeloma agents with high efficacy and acceptable tolerability add complexity to the clinical decision-making process. First, treatment of smoldering multiple myeloma remains investigational to date, although a randomized trial showed a survival gain in high-risk patients receiving lenalidomide. Second, in newly-diagnosed multiple myeloma, the majority of contemporary induction regimens have been studied in single-arm trials or compared to an older regimen, which complicates evidence-based treatment selection.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research